INTERMUNE, INC.
🏢 View company profile →52Patents
46Active
52Granted
52Portfolio score
Filing activity: Apr 15, 1983 → Jun 27, 2019 · 22 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7491794B2 | Macrocyclic compounds as inhibitors of viral replication | Human Necessities | 109 | Expired |
| US8119592B2 | Compounds and methods for inhibiting hepatitis C viral replication | Chemistry; Metallurgy | 50 | Active |
| US8299021B2 | Macrocyclic inhibitors of hepatitis C virus replication | Emerging Cross-Sectional Technologies | 45 | Active |
| US7728013B2 | Method of modulating stress-activated protein kinase system | Emerging Cross-Sectional Technologies | 35 | Active |
| US7407973B2 | Use of pirfenidone in therapeutic regimens | Emerging Cross-Sectional Technologies | 27 | Expired |
| US7696236B2 | Method of providing pirfenidone therapy to a patient | Human Necessities | 26 | Active |
| US7767700B2 | Method of providing pirfenidone therapy to a patient | Human Necessities | 20 | Active |
| US7829665B2 | Macrocyclic inhibitors of hepatitis C virus replication | Emerging Cross-Sectional Technologies | 19 | Active |
| US7816383B1 | Methods of administering pirfenidone therapy | Emerging Cross-Sectional Technologies | 18 | Active |
| US8420674B2 | Method of providing pirfenidone therapy to a patient | Human Necessities | 15 | Active |
| US7566729B1 | Modifying pirfenidone treatment for patients with atypical liver function | Emerging Cross-Sectional Technologies | 13 | Active |
| US8741936B2 | Method of modulating stress-activated protein kinase system | Emerging Cross-Sectional Technologies | 11 | Active |
| US9359379B2 | Anti-fibrotic pyridinones | Chemistry; Metallurgy | 11 | Active |
| US9675593B2 | Anti-fibrotic pyridinones | Chemistry; Metallurgy | 9 | Active |
| US7635707B1 | Pirfenidone treatment for patients with atypical liver function | Emerging Cross-Sectional Technologies | 9 | Active |
| US7767225B2 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | Emerging Cross-Sectional Technologies | 8 | Active |
| US8084475B2 | Pirfenidone therapy and inducers of cytochrome P450 | Emerging Cross-Sectional Technologies | 7 | Active |
| US8304413B2 | Compounds and methods for treating inflammatory and fibrotic disorders | Chemistry; Metallurgy | 7 | Active |
| US8975235B2 | Lysophosphatidic acid receptor antagonists | Chemistry; Metallurgy | 6 | Active |
| US8013002B2 | Methods of administering pirfenidone therapy | Emerging Cross-Sectional Technologies | 6 | Active |
| US7910610B1 | Methods of administering pirfenidone therapy | Emerging Cross-Sectional Technologies | 6 | Active |
| US7781474B2 | Inhibitors of hepatitis C virus replication | Chemistry; Metallurgy | 6 | Active |
| US9290450B2 | Compounds and methods for treating inflammatory and fibrotic disorders | Chemistry; Metallurgy | 5 | Active |
| US7988994B2 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | Emerging Cross-Sectional Technologies | 5 | Active |
| US8383150B2 | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients | Emerging Cross-Sectional Technologies | 4 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.